Clinical Trial Update: Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating disitamab vedotin combined with tislelizumab for Her2-overexpressing high-risk non-muscle invasive bladder urothelial carcinoma that is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Urothelial Carcinoma
• Overexpressing Bladder Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Status: UNKNOWN